Nifoxipam
Benzodiazepine designer drug
From Wikipedia, the free encyclopedia
Nifoxipam (3-hydroxydesmethylflunitrazepam, DP 370) is a benzodiazepine that is a minor metabolite of flunitrazepam and has been sold online as a designer drug.[1][2][3][4][5][6][7][8][9]
Legal status
- AU: Unscheduled
- BR: Class B1 (Psychoactive drugs)
- CA: Schedule IV
- DE: NpSG (Industrial and scientific use only)
- UK: Under Psychoactive Substances Act
- US: Unscheduled
- UN: Unscheduled
- In general legal for medical and research uses.
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.440.630 |
| Chemical and physical data | |
| Formula | C15H10FN3O4 |
| Molar mass | 315.260 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Nifoxipam produces strong tranquillising and sleep-prolonging effects and has much lower toxicity compared to lormetazepam and flunitrazepam in mice.[1]